Insider Selling: Replimune Group, Inc. (NASDAQ:REPL) CFO Sells $204,885.55 in Stock

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) CFO Jean M. Franchi sold 11,351 shares of the stock in a transaction that occurred on Tuesday, May 16th. The shares were sold at an average price of $18.05, for a total transaction of $204,885.55. Following the sale, the chief financial officer now directly owns 128,748 shares in the company, valued at $2,323,901.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Replimune Group Stock Down 0.3 %

Shares of REPL stock opened at $19.58 on Friday. Replimune Group, Inc. has a 52-week low of $13.54 and a 52-week high of $29.52. The company has a quick ratio of 23.58, a current ratio of 23.58 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average price is $18.02 and its two-hundred day moving average price is $21.87.

Wall Street Analysts Forecast Growth

REPL has been the topic of several research analyst reports. HC Wainwright increased their price target on shares of Replimune Group from $48.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, February 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $44.00 price objective on shares of Replimune Group in a research note on Monday, April 17th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $51.67.

Hedge Funds Weigh In On Replimune Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co NY raised its holdings in Replimune Group by 41.1% in the third quarter. Metropolitan Life Insurance Co NY now owns 2,452 shares of the company’s stock worth $42,000 after purchasing an additional 714 shares during the period. Point72 Hong Kong Ltd raised its holdings in Replimune Group by 449.3% in the third quarter. Point72 Hong Kong Ltd now owns 3,252 shares of the company’s stock worth $56,000 after purchasing an additional 2,660 shares during the period. Robeco Institutional Asset Management B.V. acquired a new stake in Replimune Group in the first quarter worth $63,000. Allspring Global Investments Holdings LLC acquired a new stake in Replimune Group in the first quarter worth $64,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Replimune Group by 17.7% in the first quarter. Ameritas Investment Partners Inc. now owns 3,748 shares of the company’s stock worth $66,000 after purchasing an additional 564 shares during the period. 87.83% of the stock is owned by institutional investors.

Replimune Group Company Profile

(Get Rating)

Replimune Group, Inc is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm’s Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response.